Saturday, 5 September 2026European Markets

ALMUNDA PRO NV And NEURONES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - almunda pro nv (amund.as) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
almunda pro nv (amund.as) €1.13 5.22% 6.32%
neurones (nro.pa) €45.80 2.61% 14.87%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. almunda pro nv (amund.as)

5.22% forward dividend yield and 6.32% return on equity

almunda professionals n.v. provides digital transformation, data management, regulatory change, and consultancy services in the netherlands and internationally. the company was formerly known as novisource n.v. and changed its name to almunda professionals n.v. in august 2021. almunda professionals n.v. was founded in 2001 and is headquartered in amsterdam, the netherlands.

earnings per share

as for profitability, almunda pro nv has a trailing twelve months eps of €0.02.

pe ratio

almunda pro nv has a trailing twelve months price to earnings ratio of 56.5. meaning, the purchaser of the share is investing €56.5 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.32%.

volume

today's last reported volume for almunda pro nv is 78 which is 95.06% below its average volume of 1581.

revenue growth

year-on-year quarterly revenue growth grew by 20.3%, now sitting on 30.01m for the twelve trailing months.

yearly top and bottom value

almunda pro nv's stock is valued at €1.13 at 02:30 est, way under its 52-week high of €1.34 and higher than its 52-week low of €1.08.

more news about almunda pro nv.

2. neurones (nro.pa)

2.61% forward dividend yield and 14.87% return on equity

neurones s.a., an information technology (it) services company, provides infrastructure, application, and consulting services in france and internationally. its infrastructure services include infrastructure management, manages public and private cloud services, it operations, user support, devops, cybersecurity, it service management, information system governance, and automation. the company also provides application services in the areas of sap, digital, web, mobility, ux/ui, enterprise content and document management, business process management, robotic process automation, dematerialization, it consulting for finance, big data, and devops, it training and change management, and innovation connected devices (iot). in addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, devops, ci/cd, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, ux/ui, and digital marketing, as well as internal process digitization, ecm/bpm, rpa, dematerialization, ai, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. the company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. neurones s.a. was founded in 1984 and is based in nanterre, france.

earnings per share

as for profitability, neurones has a trailing twelve months eps of €1.96.

pe ratio

neurones has a trailing twelve months price to earnings ratio of 23.37. meaning, the purchaser of the share is investing €23.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.87%.

volume

today's last reported volume for neurones is 2114 which is 75.38% below its average volume of 8587.

more news about neurones.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com